Compare Neurocrine Biosciences Inc (NBIX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PulteGroup, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while PulteGroup, Inc. trades at $118.95 (market cap $22.87B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PHM | |
|---|---|---|
Market Cap | $15.77B | $22.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $142.56 |
52-Week Low | $123.10 | $110.11 |
Enterprise Value | $15.78B | $23.28B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PulteGroup (PHM) trades at $120.07, down 3.52% on the day, reflecting recent market pressure amid rising bond yields and mortgage rates. The stock shows mixed technical signals with a bearish moving average trend but oversold RSI levels. Fundamentally, PHM maintains solid profitability with a net margin of 11.62% and ROE of 14.9%, though recent quarters saw two EPS misses. The company continues expansion in Florida and declared a $0.26 quarterly dividend, payable October 2, 2026.
The outlook is cautious near-term due to housing affordability concerns, but PHM's valuation appears reasonable with a P/E of 12.26. Analyst consensus leans bullish with a $137.57 price target, suggesting 14.6% upside. Key risks include interest rate sensitivity and economic slowdown impacts on homebuyer demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
